Gordon Chen

Jun 24, 2024 | onlinelibrary.wiley.com | Vikram Rao |Gordon Chen |Elaine Koh |Jonathan Segal

Editors, We read with interest the paper by Yiu et al. who studied the concept of drug persistence in inflammatory bowel disease.1 Using this, the authors highlight the superior persistence of ustekinumab and vedolizumab over tumour necrosis factor inhibitors, suggesting its utility for making clinical decisions regarding biologic therapy. We commend the authors for this piece of work but have some considerations regarding the use of drug persistence as a measure of effectiveness.